These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 2238717)
41. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912 [TBL] [Abstract][Full Text] [Related]
42. [Changes in the immune status of peptic ulcer patients after combined treatment including deep massage]. Aksenova AM; Teslenko OI; Boganskaia OA Vopr Kurortol Fizioter Lech Fiz Kult; 1999; (2):19-20. PubMed ID: 10358996 [TBL] [Abstract][Full Text] [Related]
43. [Current trends in medical therapy of gastroduodenal ulcer]. Grassi M; Fraioli A; Messina B Clin Ter; 1987 Dec; 123(6):475-86. PubMed ID: 2902954 [No Abstract] [Full Text] [Related]
44. [Causes of postoperative recurrence and therapy of peptic ulcer]. Grigor'ev PIa; Isakov VA; Iakovenko EP; Vdovichenko VI Klin Med (Mosk); 1990 Jan; 68(1):136-44. PubMed ID: 2335916 [No Abstract] [Full Text] [Related]
45. [What is the role of H2 receptor blockers today in ulcer therapy?]. Creutzfeldt W Internist (Berl); 1996 Sep; 37(9):937-8. PubMed ID: 8964690 [No Abstract] [Full Text] [Related]
46. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. Brzozowski T; Konturek PC; Sliwowski Z; Kwiecień S; Drozdowicz D; Pawlik M; Mach K; Konturek SJ; Pawlik WW J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():67-79. PubMed ID: 17033106 [TBL] [Abstract][Full Text] [Related]
53. Gastrointestinal bleeding in the critically ill: a penny saved... Baldwin TL; Clement DJ Am J Gastroenterol; 1995 Aug; 90(8):1355-6. PubMed ID: 7639253 [No Abstract] [Full Text] [Related]
54. The development of clinical practice guidelines for treatment of peptic acid diseases in a VA ambulatory care clinic--a comment. Holt RJ; Fort J Pharmacotherapy; 1996; 16(3):480-1; discussion 482-3. PubMed ID: 8726612 [No Abstract] [Full Text] [Related]
55. Peptic ulcer disease in children and adolescents: evolving dilemmas. Nord KS J Pediatr Gastroenterol Nutr; 1983; 2(3):397-9. PubMed ID: 6312009 [No Abstract] [Full Text] [Related]
56. [Ulcer prevention during anti-rheumatism therapy and in intensive medicine]. Koelz HR Schweiz Rundsch Med Prax; 1994 Jun; 83(25-26):768-71. PubMed ID: 8029591 [TBL] [Abstract][Full Text] [Related]
57. Agents with tricyclic structures for treating peptic ulcer disease. Berardi RR; Caplan NB Clin Pharm; 1983; 2(5):425-31. PubMed ID: 6354568 [TBL] [Abstract][Full Text] [Related]
58. [New approach to the treatment and prophylaxis of NSAID-induced gastropathies in ambulatory practics]. Burkov SG; Arutiunov AT; Nikiforov PA Eksp Klin Gastroenterol; 2007; (5):96-102. PubMed ID: 18389605 [No Abstract] [Full Text] [Related]
59. [Long-term drug therapy of peptic ulcer disease. A current review of the status of various anti-ulcer drugs]. Rohner HG; Rüther N Fortschr Med; 1986 Dec; 104(3):933-6. PubMed ID: 2881868 [No Abstract] [Full Text] [Related]
60. [The characteristics of the present-day course of peptic ulcer in childhood and the approaches to the staged treatment of patients]. Zakomernyĭ AG Ter Arkh; 1995; 67(2):23-6. PubMed ID: 7725252 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]